We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-0.56%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$15.7B
AUM Growth
-$1.33B
(-7.8%)
Cap. Flow
-$153M
Cap. Flow
% of AUM
-0.98%
Top 10 Holdings %
Top 10 Hldgs %
39.89%
Holding
471
New
38
Increased
139
Reduced
173
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$70.7M |
| 2 |
Meta Platforms (Facebook)
META
|
+$66.5M |
| 3 |
Becton Dickinson
BDX
|
+$61.6M |
| 4 |
GitLab
GTLB
|
+$58.7M |
| 5 |
Teradyne
TER
|
+$58.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$85.2M |
| 2 |
Steris
STE
|
+$78.2M |
| 3 |
CVS Health
CVS
|
+$62.9M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$61.9M |
| 5 |
FIVE9
FIVN
|
+$58.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.08% |
| 2 | Industrials | 22.24% |
| 3 | Healthcare | 19.2% |
| 4 | Financials | 15.72% |
| 5 | Communication Services | 5.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Edwards Lifesciences
EW
$49.2B
| $8.06M | 0.05% |
97,568
+2,954
| +3% | +$284K |
|
202
Citizens Financial Group
CFG
$29.5B
| $8.01M | 0.05% |
233,161
-35,317
| -13% | -$1.31M |
|
|
SCHW
203
Charles Schwab
SCHW
$187B
| $7.98M | 0.05% |
+111,086
| New | +$7.71M |
|
204
PayPal
PYPL
$45.8B
| $7.48M | 0.05% |
86,941
+19,648
| +29% | +$1.74M |
|
205
Envista
NVST
$4.02B
| $7.44M | 0.05% |
226,888
-1,428,768
| -86% | -$54.1M |
|
|
CFLT
206
DELISTED
Confluent
CFLT
| $7.38M | 0.05% |
+310,569
| New | +$8.37M |
|
207
Cerus
CERS
$508M
| $7.32M | 0.05% |
2,033,336
+162,346
| +9% | +$777K |
|
208
Morgan Stanley
MS
$317B
| $6.76M | 0.04% |
85,626
-23,316
| -21% | -$1.97M |
|
209
Cognex
CGNX
$10B
| $6.48M | 0.04% |
156,402
+93,229
| +148% | +$4.22M |
|
210
Enterprise Financial Services Corp
EFSC
$2.31B
| $6.41M | 0.04% |
145,628
-29,513
| -17% | -$1.34M |
|
211
S&P Global
SPGI
$122B
| $6.37M | 0.04% |
20,846
+3,648
| +21% | +$1.31M |
|
|
FRC
212
DELISTED
First Republic Bank
FRC
| $6.3M | 0.04% |
48,283
-324
| -0.7% | -$49.8K |
|
|
LTHM
213
DELISTED
Livent Corporation
LTHM
| $6.12M | 0.04% |
199,511
+65,034
| +48% | +$1.82M |
|
214
Albemarle
ALB
$13.4B
| $6.05M | 0.04% |
22,888
-3,227
| -12% | -$821K |
|
|
CMA
215
DELISTED
Comerica
CMA
| $6.05M | 0.04% |
+85,046
| New | +$6.7M |
|
|
INFI
216
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $5.95M | 0.04% |
5,000,000
| – | – |
|
217
Zai Lab
ZLAB
$2.78B
| $5.87M | 0.04% |
171,651
+27,654
| +19% | +$1.18M |
|
218
Amgen
AMGN
$204B
| $5.74M | 0.04% |
25,461
-3,256
| -11% | -$789K |
|
219
Deere & Co
DE
$185B
| $5.4M | 0.03% |
16,186
+1,230
| +8% | +$421K |
|
220
Cullen/Frost Bankers
CFR
$10.1B
| $5.27M | 0.03% |
+39,883
| New | +$5.23M |
|
221
Sabre
SABR
$868M
| $5.26M | 0.03% |
1,021,602
+24,113
| +2% | +$161K |
|
222
Medtronic
MDT
$120B
| $5.22M | 0.03% |
64,626
+7,681
| +13% | +$690K |
|
223
Chemed
CHE
$6.65B
| $5.11M | 0.03% |
11,706
-1,067
| -8% | -$513K |
|
224
Biomea Fusion
BMEA
$123M
| $4.89M | 0.03% |
500,000
+466,845
| +1,408% | +$5.36M |
|
225
Veeva Systems
VEEV
$43.5B
| $4.87M | 0.03% |
29,518
+17,904
| +154% | +$3.58M |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q3 2022 Portfolio in Review
As of Q3 2022, Polar Capital Holdings held 471 positions worth $15.7B, down 7.8% from $17B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Polar Capital Holdings's Q3 2022 filing shows 38 new, 139 increased, 173 reduced and 54 closed positions. Its largest new stake was DexCom: 834,956 shares worth $67.2M. The largest sale was Adobe, an estimated $85.2M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Industrials and Healthcare.
- Polar Capital Holdings's largest Q3 2022 buy was DexCom: 834,956 shares worth $67.2M.
- Polar Capital Holdings added most to Meta Platforms (Facebook) in Q3 2022, an estimated $66.5M increase.
- Polar Capital Holdings's biggest Q3 2022 reduction was Neurocrine Biosciences, cutting an estimated $61.9M.
- Polar Capital Holdings fully exited Adobe in Q3 2022, selling an estimated $85.2M.
- Polar Capital Holdings's ten largest holdings make up 40% of its $15.7B portfolio in Q3 2022.
- Polar Capital Holdings opened 38 new positions and closed 54 in Q3 2022.
- Polar Capital Holdings's portfolio value fell 7.8% quarter-over-quarter to $15.7B.
Based on Polar Capital Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.